Crohn’s Disease – Epidemiology, Clinical Presentation and Treatment Possibilities
DOI:
https://doi.org/10.12775/QS.2025.53.69962Keywords
Crohn’s disease, inflammatory bowel disease, inflammation, treatment, surgeryAbstract
Introduction. Crohn’s disease is a chronic, relapsing–remitting inflammatory disorder of the gastrointestinal tract. Once concentrated primarily in high-income regions, Crohn’s disease has now become a global condition. Advances in understanding immune and stromal cell populations, their interactions, and the cytokine and chemokine networks that drive pathogenesis and rapid technological progress have greatly broadened therapeutic options. Currently treatment strategies aim not only to induce and maintain deep, durable remission, but also to prevent complications and slow or stop the progressive nature of the disease.
Aim. The aim of this review is to summarize current evidence of epidemiology, pathophysiology, diagnosis, and treatment options in Crohn’s disease.
Material and methods. This research involves a review of literature found in PubMed, Google Scholar, electronic databases, and books using key words combinations such as “Crohn’s disease”, “symptoms”, “epidemiology”, “and”, “treatment”, “clinical trial”, “risk factors”, “pathogenesis”, “surgery”.
Conclusions. Despite advancements in Crohn’s disease treatment, recurrence rate is still at high levels resulting in the need for surgical management for the majority of patients diagnosed with Crohn’s disease. Further studies are still necessary to confirm efficacy and potential of existing treatment options and to search for new substances, which might be effective in Crohn’s disease management.
References
Dolinger, M., Torres, J., & Vermeire, S. (2024). Crohn's disease. Lancet (London, England), 403(10432), 1177–1191. https://doi.org/10.1016/S0140-6736(23)02586-2
Veauthier, B., & Hornecker, J. R. (2018). Crohn's Disease: Diagnosis and Management. American family physician, 98(11), 661–669.
Torres, J., Mehandru, S., Colombel, J. F., & Peyrin-Biroulet, L. (2017). Crohn's disease. Lancet (London, England), 389(10080), 1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., Sung, J. J. Y., & Kaplan, G. G. (2017). Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet (London, England), 390(10114), 2769–2778. https://doi.org/10.1016/S0140-6736(17)32448-0
Wilkens, R., Dolinger, M., Burisch, J., & Maaser, C. (2022). Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology, 162(5), 1476–1492. https://doi.org/10.1053/j.gastro.2021.10.052
Jairath, V., & Feagan, B. G. (2020). Global burden of inflammatory bowel disease. The lancet. Gastroenterology & hepatology, 5(1), 2–3. https://doi.org/10.1016/S2468-1253(19)30358-9
Caron, B., Honap, S., & Peyrin-Biroulet, L. (2024). Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. Journal of Crohn's & colitis, 18(Supplement_2), ii3–ii15. https://doi.org/10.1093/ecco-jcc/jjae082
Burisch, J., & Munkholm, P. (2013). Inflammatory bowel disease epidemiology. Current opinion in gastroenterology, 29(4), 357–362. https://doi.org/10.1097/MOG.0b013e32836229fb
Mak, W. Y., Zhao, M., Ng, S. C., & Burisch, J. (2020). The epidemiology of inflammatory bowel disease: East meets west. Journal of gastroenterology and hepatology, 35(3), 380–389. https://doi.org/10.1111/jgh.14872
Kaplan, G. G., & Ng, S. C. (2017). Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology, 152(2), 313–321.e2. https://doi.org/10.1053/j.gastro.2016.10.020
Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., & Kaplan, G. G. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142(1), 46–e30. https://doi.org/10.1053/j.gastro.2011.10.001
Mahid, S. S., Minor, K. S., Soto, R. E., Hornung, C. A., & Galandiuk, S. (2006). Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic proceedings, 81(11), 1462–1471. https://doi.org/10.4065/81.11.1462
Kondo, K., Ohfuji, S., Watanabe, K., Yamagami, H., Fukushima, W., Ito, K., Suzuki, Y., Hirota, Y., & Japanese Case-Control Study Group for Crohn's disease (2019). The association between environmental factors and the development of Crohn's disease with focusing on passive smoking: A multicenter case-control study in Japan. PloS one, 14(6), e0216429. https://doi.org/10.1371/journal.pone.0216429
Ananthakrishnan, A. N., Khalili, H., Konijeti, G. G., Higuchi, L. M., de Silva, P., Fuchs, C. S., Willett, W. C., Richter, J. M., & Chan, A. T. (2014). Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut, 63(5), 776–784. https://doi.org/10.1136/gutjnl-2013-305304
Popa, S. L., Pop, C., & Dumitrascu, D. L. (2020). Diet Advice for Crohn's Disease: FODMAP and Beyond. Nutrients, 12(12), 3751. https://doi.org/10.3390/nu12123751
Ungaro, R., Bernstein, C. N., Gearry, R., Hviid, A., Kolho, K. L., Kronman, M. P., Shaw, S., Van Kruiningen, H., Colombel, J. F., & Atreja, A. (2014). Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. The American journal of gastroenterology, 109(11), 1728–1738. https://doi.org/10.1038/ajg.2014.246
Cornish, J. A., Tan, E., Simillis, C., Clark, S. K., Teare, J., & Tekkis, P. P. (2008). The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. The American journal of gastroenterology, 103(9), 2394–2400. https://doi.org/10.1111/j.1572-0241.2008.02064.x
Ananthakrishnan, A. N., Higuchi, L. M., Huang, E. S., Khalili, H., Richter, J. M., Fuchs, C. S., & Chan, A. T. (2012). Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Annals of internal medicine, 156(5), 350–359. https://doi.org/10.7326/0003-4819-156-5-201203060-00007
Ungaro, R., Chang, H. L., Côté-Daigneault, J., Mehandru, S., Atreja, A., & Colombel, J. F. (2016). Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease. The American journal of gastroenterology, 111(10), 1416–1423. https://doi.org/10.1038/ajg.2016.233
Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J. P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J. F., Sahbatou, M., & Thomas, G. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 411(6837), 599–603. https://doi.org/10.1038/35079107
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., Achkar, J. P., Brant, S. R., Bayless, T. M., Kirschner, B. S., Hanauer, S. B., Nuñez, G., & Cho, J. H. (2001). A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 411(6837), 603–606. https://doi.org/10.1038/35079114
Okai, N., Watanabe, T., Minaga, K., Kamata, K., Honjo, H., & Kudo, M. (2022). Alterations of autophagic and innate immune responses by the Crohn's disease-associated ATG16L1 mutation. World journal of gastroenterology, 28(26), 3063–3070. https://doi.org/10.3748/wjg.v28.i26.3063
Zhang, L., Lu, Y., Ge, Y., Shi, Y., Wu, X., Xu, Q., Li, X., Lu, L., Zhang, F., & Yao, G. (2015). Interleukin-23R rs7517847 T/G Polymorphism Contributes to the Risk of Crohn's Disease in Caucasians: A Meta-Analysis. Journal of immunology research, 2015, 279849. https://doi.org/10.1155/2015/279849
Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F. M., Briggs, J., Günther, S., Prescott, N. J., Onnie, C. M., Häsler, R., Sipos, B., Fölsch, U. R., Lengauer, T., Platzer, M., Mathew, C. G., Krawczak, M., … Schreiber, S. (2007). A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature genetics, 39(2), 207–211. https://doi.org/10.1038/ng1954
Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., Ripke, S., Lee, J. C., Jostins, L., Shah, T., Abedian, S., Cheon, J. H., Cho, J., Dayani, N. E., Franke, L., Fuyuno, Y., Hart, A., Juyal, R. C., Juyal, G., Kim, W. H., … Weersma, R. K. (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature genetics, 47(9), 979–986. https://doi.org/10.1038/ng.3359
Zhu, L., Shi, T., Zhong, C., Wang, Y., Chang, M., & Liu, X. (2017). IL-10 and IL-10 Receptor Mutations in Very Early Onset Inflammatory Bowel Disease. Gastroenterology research, 10(2), 65–69. https://doi.org/10.14740/gr740w
Uniken Venema, W. T., Voskuil, M. D., Dijkstra, G., Weersma, R. K., & Festen, E. A. (2016). The genetic background of inflammatory bowel disease: from correlation to causality. The Journal of Pathology, 241(2), 146–158. Portico. https://doi.org/10.1002/path.4817
Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P., Zeissig, S., Ahmad, T., Andersen, V., Andrews, J. M., Annese, V., Brand, S., Brant, S. R., Cho, J. H., Daly, M. J., Dubinsky, M., Duerr, R. H., Ferguson, L. R., Franke, A., Gearry, R. B., Goyette, P., Hakonarson, H., … Lees, C. W. (2016). Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (London, England), 387(10014), 156–167. https://doi.org/10.1016/S0140-6736(15)00465-1
Petagna, L., Antonelli, A., Ganini, C., Bellato, V., Campanelli, M., Divizia, A., Efrati, C., Franceschilli, M., Guida, A. M., Ingallinella, S., Montagnese, F., Sensi, B., Siragusa, L., & Sica, G. S. (2020). Pathophysiology of Crohn's disease inflammation and recurrence. Biology direct, 15(1), 23. https://doi.org/10.1186/s13062-020-00280-5
Yu, C., Pan, Y., Mao, A., Zhao, Y., Liu, Q., & Hu, Y. (2025). The Role and Application of MAdCAM-1/α4β7-Induced Lymphocyte Migration in Inflammatory Enterohepatic Diseases. Biomedicines, 13(11), 2659. https://doi.org/10.3390/biomedicines13112659
Nóbrega, V. G., Silva, I. N. N., Brito, B. S., Silva, J., Silva, M. C. M. D., & Santana, G. O. (2018). THE ONSET OF CLINICAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS. Arquivos de gastroenterologia, 55(3), 290–295. https://doi.org/10.1590/S0004-2803.201800000-73
Hoekman, D. R., Zeevenhooven, J., D'Haens, G. R., & Benninga, M. A. (2017). The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. European journal of gastroenterology & hepatology, 29(9), 1086–1090. https://doi.org/10.1097/MEG.0000000000000921
Seyedian, S. S., Nokhostin, F., & Malamir, M. D. (2019). A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of medicine and life, 12(2), 113–122. https://doi.org/10.25122/jml-2018-0075
Peyrin-Biroulet, L., Loftus, E. V., Jr, Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2012). Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflammatory bowel diseases, 18(1), 43–48. https://doi.org/10.1002/ibd.21674
Rogler, G., Singh, A., Kavanaugh, A., & Rubin, D. T. (2021). Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology, 161(4), 1118–1132. https://doi.org/10.1053/j.gastro.2021.07.042
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., Burisch, J., Castiglione, F., Eliakim, R., Ellul, P., González-Lama, Y., Gordon, H., Halligan, S., Katsanos, K., Kopylov, U., Kotze, P. G., … European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] (2019). ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's & colitis, 13(2), 144–164. https://doi.org/10.1093/ecco-jcc/jjy113
Poullis, A., Foster, R., Northfield, T. C., & Mendall, M. A. (2002). Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 16(4), 675–681. https://doi.org/10.1046/j.1365-2036.2002.01196.x
Magro, F., Langner, C., Driessen, A., Ensari, A., Geboes, K., Mantzaris, G. J., Villanacci, V., Becheanu, G., Borralho Nunes, P., Cathomas, G., Fries, W., Jouret-Mourin, A., Mescoli, C., de Petris, G., Rubio, C. A., Shepherd, N. A., Vieth, M., Eliakim, R., European Society of Pathology (ESP), & European Crohn's and Colitis Organisation (ECCO) (2013). European consensus on the histopathology of inflammatory bowel disease. Journal of Crohn's & colitis, 7(10), 827–851. https://doi.org/10.1016/j.crohns.2013.06.001
Annese, V., Daperno, M., Rutter, M. D., Amiot, A., Bossuyt, P., East, J., Ferrante, M., Götz, M., Katsanos, K. H., Kießlich, R., Ordás, I., Repici, A., Rosa, B., Sebastian, S., Kucharzik, T., Eliakim, R., & European Crohn's and Colitis Organisation (2013). European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's & colitis, 7(12), 982–1018. https://doi.org/10.1016/j.crohns.2013.09.016
Gergely, M., & Deepak, P. (2022). Tools for the Diagnosis and Management of Crohn’s Disease. Gastroenterology Clinics of North America, 51(2), 213–239. https://doi.org/10.1016/j.gtc.2021.12.003
Daperno, M., D'Haens, G., Van Assche, G., Baert, F., Bulois, P., Maunoury, V., Sostegni, R., Rocca, R., Pera, A., Gevers, A., Mary, J. Y., Colombel, J. F., & Rutgeerts, P. (2004). Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal endoscopy, 60(4), 505–512. https://doi.org/10.1016/s0016-5107(04)01878-4
Mary, J. Y., & Modigliani, R. (1989). Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut, 30(7), 983–989. https://doi.org/10.1136/gut.30.7.983
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J. F., Gasche, C., Geboes, K., Jewell, D. P., Karban, A., Loftus, E. V., Jr, Peña, A. S., Riddell, R. H., Sachar, D. B., Schreiber, S., Steinhart, A. H., Targan, S. R., Vermeire, S., … Warren, B. F. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 19 Suppl A, 5A–36A. https://doi.org/10.1155/2005/269076
Levine, A., Griffiths, A., Markowitz, J., Wilson, D. C., Turner, D., Russell, R. K., Fell, J., Ruemmele, F. M., Walters, T., Sherlock, M., Dubinsky, M., & Hyams, J. S. (2011). Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflammatory bowel diseases, 17(6), 1314–1321. https://doi.org/10.1002/ibd.21493
Lee, S. H., Kwon, J. E., & Cho, M. L. (2018). Immunological pathogenesis of inflammatory bowel disease. Intestinal research, 16(1), 26–42. https://doi.org/10.5217/ir.2018.16.1.26
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016). Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. Journal of Crohn's & colitis, 10(8), 989–997. https://doi.org/10.1093/ecco-jcc/jjw053
Jang, D. I., Lee, A. H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., Lee, S. R., & Yang, S. H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. International journal of molecular sciences, 22(5), 2719. https://doi.org/10.3390/ijms22052719
Cassinotti, A., Ardizzone, S., & Porro, G. B. (2008). Adalimumab for the treatment of Crohn's disease. Biologics : targets & therapy, 2(4), 763–777. https://doi.org/10.2147/btt.s3292
Hemperly, A., & Vande Casteele, N. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical Pharmacokinetics, 57(8), 929–942. https://doi.org/10.1007/s40262-017-0627-0
Singh, S., Andersen, N. N., Andersson, M., Loftus, E. V., Jr, & Jess, T. (2018). Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study. Alimentary pharmacology & therapeutics, 47(5), 596–604. https://doi.org/10.1111/apt.14466
Singh, S., Heien, H. C., Sangaralingham, L. R., Schilz, S. R., Kappelman, M. D., Shah, N. D., & Loftus, E. V., Jr (2016). Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 14(8), 1120–1129.e6. https://doi.org/10.1016/j.cgh.2016.03.038
Vavricka, S. R., Schoepfer, A. M., Scharl, M., & Rogler, G. (2014). Steroid Use in Crohn’s Disease. Drugs, 74(3), 313–324. https://doi.org/10.1007/s40265-014-0183-y
Rezaie, A., Kuenzig, M. E., Benchimol, E. I., Griffiths, A. M., Otley, A. R., Steinhart, A. H., Kaplan, G. G., & Seow, C. H. (2015). Budesonide for induction of remission in Crohn's disease. The Cochrane database of systematic reviews, 2015(6), CD000296. https://doi.org/10.1002/14651858.CD000296.pub4
Faleck, D. M., Shmidt, E., Huang, R., Katta, L. G., Narula, N., Pinotti, R., Suarez-Farinas, M., & Colombel, J. F. (2021). Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 19(2), 238–245.e4. https://doi.org/10.1016/j.cgh.2020.06.036
Loftus, E. V., Jr, Panés, J., Lacerda, A. P., Peyrin-Biroulet, L., D'Haens, G., Panaccione, R., Reinisch, W., Louis, E., Chen, M., Nakase, H., Begun, J., Boland, B. S., Phillips, C., Mohamed, M. F., Liu, J., Geng, Z., Feng, T., Dubcenco, E., & Colombel, J. F. (2023). Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. The New England journal of medicine, 388(21), 1966–1980. https://doi.org/10.1056/NEJMoa2212728
Campregher, C., & Gasche, C. (2011). Aminosalicylates. Best Practice & Research Clinical Gastroenterology, 25(4–5), 535–546. https://doi.org/10.1016/j.bpg.2011.10.013
Lim, W. C., Wang, Y., MacDonald, J. K., & Hanauer, S. (2016). Aminosalicylates for induction of remission or response in Crohn's disease. The Cochrane database of systematic reviews, 7(7), CD008870. https://doi.org/10.1002/14651858.CD008870.pub2
Gjuladin-Hellon, T., Gordon, M., Iheozor-Ejiofor, Z., & Akobeng, A. K. (2019). Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. The Cochrane database of systematic reviews, 6(6), CD008414. https://doi.org/10.1002/14651858.CD008414.pub3
Akobeng, A. K., Zhang, D., Gordon, M., & MacDonald, J. K. (2016). Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. The Cochrane database of systematic reviews, 9(9), CD003715. https://doi.org/10.1002/14651858.CD003715.pub3
Chande, N., Townsend, C. M., Parker, C. E., & MacDonald, J. K. (2016). Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. The Cochrane database of systematic reviews, 10(10), CD000545. https://doi.org/10.1002/14651858.CD000545.pub5
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015). Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews, 2015(10), CD000067. https://doi.org/10.1002/14651858.CD000067.pub3
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W., & Chande, N. (2014). Methotrexate for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews, 2014(8), CD006884. https://doi.org/10.1002/14651858.CD006884.pub3
Słowik, J., Zapasek, D., Bajak, M., Szczepański, M., Mamczur, M., Kuliga, M., … Sowa, D. (2024). Infliximab: Pharmacological Properties, Mechanism of Action, and Clinical Applications in the Treatment of Selected Inflammatory Diseases. Quality in Sport, 36, 56477. https://doi.org/10.12775/QS.2024.36.56477
Cingoz O. (2009). Ustekinumab. mAbs, 1(3), 216–221. https://doi.org/10.4161/mabs.1.3.8593
Baker D. E. (2023). Risankizumab. Hospital pharmacy, 58(3), 244–251. https://doi.org/10.1177/0018578719873874
Peyrin-Biroulet, L., Chapman, J. C., Colombel, J. F., Caprioli, F., D'Haens, G., Ferrante, M., Schreiber, S., Atreya, R., Danese, S., Lindsay, J. O., Bossuyt, P., Siegmund, B., Irving, P. M., Panaccione, R., Cao, Q., Neimark, E., Wallace, K., Anschutz, T., Kligys, K., Duan, W. R., … SEQUENCE Study Group (2024). Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease. The New England journal of medicine, 391(3), 213–223. https://doi.org/10.1056/NEJMoa2314585
Babczyńska, M., Buliszak, A., Marcjasz, P., Bioły, A., Borończyk, A., & Zając, P. (2025). Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy. Quality in Sport, 41, 59986. https://doi.org/10.12775/QS.2025.41.59986
Di Sario, A., Sassaroli, P., Daretti, L., Annulli, G., Schiada, L., Falcioni, G., Bendia, E., Antuono, S., & Benedetti, A. (2017). Postoperative Recurrence of Crohn's Disease: Pathophysiology, Diagnosis and Treatment. Current pharmaceutical biotechnology, 18(12), 979–988. https://doi.org/10.2174/1389201019666180216152805
Fichera, A., Schlottmann, F., Krane, M., Bernier, G., & Lange, E. (2018). Role of surgery in the management of Crohn’s disease. Current Problems in Surgery, 55(5), 162–187. https://doi.org/10.1067/j.cpsurg.2018.05.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kacper Kutnik, Weronika Woźnica, Julia Dąbrowska, Jakub Lambach, Katarzyna Mazurek, Anna Gęborys, Maja Wojcieszak, Julia Matuszewska, Dominika Miazga, Alicja Maziarczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 60
Number of citations: 0
